[强]_老虎社区_美港股上老虎

AshlynnLee
2021-12-01

[强]

Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>再生元新冠抗体药物对奥密克戎病的疗效可能较差</blockquote>

Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag

Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>再生元新冠抗体药物对奥密克戎病的疗效可能较差</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":603095117,"tweetId":"603095117","gmtCreate":1638335653387,"gmtModify":1638335653387,"author":{"id":4088581130244910,"idStr":"4088581130244910","authorId":4088581130244910,"authorIdStr":"4088581130244910","name":"AshlynnLee","avatar":"https://static.tigerbbs.com/8aef70d0693abd07585f544f35472951","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>[强]&nbsp;</body></html>","htmlText":"<html><head></head><body>[强]&nbsp;</body></html>","text":"[强]","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603095117","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","kind":"news","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=zh_CN&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>再生元新冠抗体药物对奥密克戎病的疗效可能较差</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.<blockquote>11月30日（路透社）——<a href=\"https://laohu8.com/S/REGN\">再生元制药</a>该公司周二表示，该公司的COVID-19抗体药物对奥密克戎病毒的效果可能较差，在Moderna的最高老板对该公司的疫苗提出类似担忧后，这加剧了人们对现有治疗方法有效性的担忧。</blockquote> Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.<blockquote>Moderna(MRNA.O)首席执行官的言论重新引发了人们对该变种可能会拖累刚刚起步的全球经济复苏的担忧，全球市场暴跌。</blockquote> Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.<blockquote>Regeneron(REGN.O)表示，根据对奥密克戎个体突变的研究，“疫苗诱导和单克隆抗体传递免疫的中和活性可能都会降低”，并补充说，该分析包括其COVID-19抗体混合物REGEN-COV。</blockquote> The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.<blockquote>该公司表示，正在进行进一步研究，以利用该变种的基因序列量化潜在影响。</blockquote> One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.<blockquote>首席执行官莱恩·施莱弗(Len Schleifer)在接受CNBC采访时表示，治疗中使用的一种抗体可能会受到影响，而另一种则不会受到影响。</blockquote> \"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"<blockquote>\"<a href=\"https://laohu8.com/S/JE\">刚刚</a>就像疫苗必须适应一样，我们可能必须不断适应我们的单克隆抗体。”</blockquote> <a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.<blockquote><a href=\"https://laohu8.com/S/LLY\">礼来公司和</a>Co(LLY.N)在一份电子邮件声明中告诉路透社，该公司也在努力了解其疗法对奥密克戎的中和活性。</blockquote> Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.<blockquote>Regeneron股价在早盘交易中下跌约3%，Lillyshed股价下跌2.5%。</blockquote> Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.<blockquote>竞争对手Vir Biotechnology Inc(VIR.O)表示，基于奥密克戎序列，其抗体疗法sotrovimab可能会保持针对该变种的效力。</blockquote> The company is \"working to confirm this in the lab as a matter of urgency\", it added.<blockquote>它补充说，该公司正在“紧急努力在实验室中确认这一点”。</blockquote> Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron<blockquote>吉利德公司(GILD.O)表示，相信其静脉注射疗法瑞德西韦(Remdesivir)是目前唯一被批准用于治疗COVID-19的抗病毒药物，将继续有效对抗目前已确定的变种，包括奥密克戎病毒</blockquote> The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.<blockquote>美国食品和药物管理局周二表示，正在评估授权的COVID-19疫苗针对奥密克戎病毒的有效性，并预计在未来几周内获得更多信息。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>再生元新冠抗体药物对奥密克戎病的疗效可能较差</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>再生元新冠抗体药物对奥密克戎病的疗效可能较差</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-12-01 11:45\n\n</h4>\n</header>\n<article>\nNov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.<blockquote>11月30日（路透社）——<a href=\"https://laohu8.com/S/REGN\">再生元制药</a>该公司周二表示，该公司的COVID-19抗体药物对奥密克戎病毒的效果可能较差，在Moderna的最高老板对该公司的疫苗提出类似担忧后，这加剧了人们对现有治疗方法有效性的担忧。</blockquote> Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.<blockquote>Moderna(MRNA.O)首席执行官的言论重新引发了人们对该变种可能会拖累刚刚起步的全球经济复苏的担忧，全球市场暴跌。</blockquote> Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.<blockquote>Regeneron(REGN.O)表示，根据对奥密克戎个体突变的研究，“疫苗诱导和单克隆抗体传递免疫的中和活性可能都会降低”，并补充说，该分析包括其COVID-19抗体混合物REGEN-COV。</blockquote> The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.<blockquote>该公司表示，正在进行进一步研究，以利用该变种的基因序列量化潜在影响。</blockquote> One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.<blockquote>首席执行官莱恩·施莱弗(Len Schleifer)在接受CNBC采访时表示，治疗中使用的一种抗体可能会受到影响，而另一种则不会受到影响。</blockquote> \"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"<blockquote>\"<a href=\"https://laohu8.com/S/JE\">刚刚</a>就像疫苗必须适应一样，我们可能必须不断适应我们的单克隆抗体。”</blockquote> <a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.<blockquote><a href=\"https://laohu8.com/S/LLY\">礼来公司和</a>Co(LLY.N)在一份电子邮件声明中告诉路透社，该公司也在努力了解其疗法对奥密克戎的中和活性。</blockquote> Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.<blockquote>Regeneron股价在早盘交易中下跌约3%，Lillyshed股价下跌2.5%。</blockquote> Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.<blockquote>竞争对手Vir Biotechnology Inc(VIR.O)表示，基于奥密克戎序列，其抗体疗法sotrovimab可能会保持针对该变种的效力。</blockquote> The company is \"working to confirm this in the lab as a matter of urgency\", it added.<blockquote>它补充说，该公司正在“紧急努力在实验室中确认这一点”。</blockquote> Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron<blockquote>吉利德公司(GILD.O)表示，相信其静脉注射疗法瑞德西韦(Remdesivir)是目前唯一被批准用于治疗COVID-19的抗病毒药物，将继续有效对抗目前已确定的变种，包括奥密克戎病毒</blockquote> The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.<blockquote>美国食品和药物管理局周二表示，正在评估授权的COVID-19疫苗针对奥密克戎病毒的有效性，并预计在未来几周内获得更多信息。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","GILD":"吉利德科学"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1,"symbols_score_info":{"MRNA":0.9,"REGN":0.9,"GILD":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":1931,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>再生元新冠抗体药物对奥密克戎病的疗效可能较差</blockquote>

评论（1）

热议股票